AKEBIA THERAPEUTICS I

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

03 4 2025 07:00:01 提供 Nasdaq GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 4 2025 15:05:00 提供 Nasdaq GlobeNewswire

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

25 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

19 3 2025 21:17:53 提供 Nasdaq GlobeNewswire

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

19 3 2025 15:01:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: AKEBIA THERAPEUTICS INC. - COMMON STOCK

19 3 2025 09:01:40 提供 NetDania Notify

NetDania - New 12 months High: AKEBIA THERAPEUTICS INC. - COMMON STOCK

18 3 2025 12:14:28 提供 NetDania Notify

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

13 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

06 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 3 2025 15:05:00 提供 Nasdaq GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 2 2025 15:05:00 提供 Nasdaq GlobeNewswire